reverse-phase HPLC comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-09-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
| Property | Value | Notes |
|---|---|---|
| Analytical method | LC-MS/MS | Preferred confirmatory technique |
| Appearance | White to off-white powder | Lyophilised form |
| Solubility | Freely soluble in water | Also described in saline |
| Storage temperature | Below -20 °C for powder | Short-term refrigeration for solutions |
| Regulatory status | Prohibited in sport | Listed under peptide hormones |
Reconstitution of a lyophilized peptide is normally done with sterile water or a suitable buffer under aseptic conditions. Adding solvent down the vial wall and allowing gentle dissolution instead of vigorous vortexing reduces the chance of aggregation, which can lower the effective concentration of the resulting solution. Concentrated stocks are usually diluted into working buffer shortly before use. Because no standard preparation protocol exists for TB-500 specifically, laboratories adapt general peptide handling practice, and reported results may reflect differing preparation choices.
Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.
Storage recommendations center on keeping the dry powder cold, dry, and dark. A freezer at -20 degrees Celsius or below is conventional, and desiccant is often included to limit moisture uptake. Once dissolved, the peptide is less stable, and solutions are typically kept frozen and thawed only once. Repeated freeze-thaw cycles are a common source of losses because they promote aggregation and adsorption to container surfaces. Working aliquots are therefore prepared in advance, and glass or low-binding plastic is usually preferred over ordinary laboratory plastic.
Identity and purity are assessed with a small set of standard techniques. Reverse-phase high-performance liquid chromatography gives a purity estimate from peak area, usually recorded at 214 or 220 nanometers, where the peptide bond absorbs. Mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidized species. Amino acid analysis or tandem mass spectrometry sequencing can verify the sequence itself. Additional quality attributes include water content, residual trifluoroacetic acid carried over from purification, and endotoxin where the material is intended for biological work.
The compound is most often distributed as a lyophilized powder, appearing white to off-white and forming a loose cake or fluffy solid. It is hygroscopic to some degree, so brief exposure to humid air can add water weight and complicate weighing. The peptide dissolves readily in water and in neutral aqueous buffers, and aqueous solubility is generally described as high, well above the concentrations used in typical assays. Some polar organic solvents are also usable, which matters when a concentrated stock is prepared before dilution into buffer.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
== History == In 1942, James Hamilton observed that prepubertal castration prevents the later development of male pattern baldness in mature men. In 1974, Julianne Imperato-McGinley of Cornell Medical College in New York attended a conference on birth defects. She reported on a group of intersex children in the Caribbean who appeared sexually ambiguous at birth, and were initially raised as girls, but then grew external male genitalia and other masculine characteristic after onset of puberty. These children, despite being raised as girls until puberty, were generally heterosexual and were termed "Guevedoces" by their local community, which means "penis at twelve" in Spanish. Her research group found these children shared a genetic mutation, causing deficiency of the 5α-reductase enzyme and male hormone dihydrotestosterone (DHT), which was found to have been the etiology behind abnormalities in male sexual development. Upon maturation, these individuals were observed to have smaller prostates which were underdeveloped, and were also observed to lack incidence of male pattern baldness. In 1975, copies of Imperato-McGinley's presentation were seen by P. Roy Vagelos, who was then serving as Merck's basic research chief. He was intrigued by the notion that decreased levels of DHT led to the development of smaller prostates. Dr. Vagelos then sought to create a drug that could mimic the condition found in these children to treat older men who had benign prostatic hyperplasia. Finasteride was developed by Merck under the code name MK-906.
In 2004, LSBC announced an agreement with Sigma-Aldritch under which LSB would produce recombinant aprotinin in plants of the tobacco family and Sigma-Aldrich would commercially distribute LSBC's recombinant product to its customers in the R&D, cell culture and manufacturing markets. As of October 2012 SIgma still has the protein in stock. Meristem Therapeutics – Lipase, lactoferrin, plasma proteins, collagen, antibodies (IgA, IgM), allergens and protease inhibitors in tobacco. Liquidated in 2008. Novoplant GmgH – therapeutic proteins in tobacco and feed peas. Conducted field trials in US of feed peas for pigs that produced anti-bacterial antibodies. Former CSO is now with another company; appears that Novoplant is out of business. Monsanto Company – abandoned development of pharmaceutical producing corn PPL Therapeutics – Alpha 1-antitrypsin for cystic fibrosis and emphysema in sheep milk. This is the company that created Dolly the Sheep, the first cloned animal. Went bankrupt in 2004. Assets were acquired by Pharming and an investment group including University of Pittsburgh Medical Center. SemBioSys – insulin in safflower. In May 2012, SemBioSys terminated its operations.
=== Personal life and death === Dyson married his first wife, the Swiss mathematician Verena Huber, on 11 August 1950. They had two children, Esther and George, before divorcing in 1958. In November 1958 he married Imme Jung, with whom he had four daughters. Dyson died on 28 February 2020 at Penn Medicine Princeton Medical Center in Plainsboro Township, New Jersey, from complications following a fall. He was 96.
== Sources == Cole, R D (1996), "Choh Hao Li: April 21, 1913 - November 28, 1987", Biographical Memoirs of the National Academy of Sciences, vol. 70, pp. 221–39, PMID 11619324 Hruby, Victor J.; Yamashiro, Donald (1988), "Memorial issue in honor of Professor Choh Hao Li. Part I", Int. J. Pept. Protein Res, vol. 32, no. 6 (published Dec 1988), pp. 417–598, doi:10.1111/j.1399-3011.1988.tb01371.x, PMID 3073145 Hruby, V J (1988), "In memoriam Choh Hao Li, April 21, 1913-November 28, 1987", Int. J. Pept. Protein Res, vol. 31, no. 3 (published Mar 1988), pp. 253–4, PMID 3286549 "Classic pages in Obstetrics and Gynecology. Interstitial cell stimulating hormone. II. Method of preparation and some physico-chemical studies, by Choh Hao Li, Miriam E. Simpson, and Herbert M. Evans. Endocrinology, vol. 27, pp. 803–808, 1940", Am. J. Obstet. Gynecol, vol. 17, no. 5 (published Nov 1, 1973), p. 716, 1973, PMID 4599575 "Choh Hao Li", Triangle; the Sandoz Journal of Medical Science, vol. 9, no. 1, pp. 41–2, 1969, ISSN 0041-2597, PMID 4896971 Ingle, D J; Nezamis, J E; Moreley, E H; Li, C H (1953), "The effect of some partially purified preparations of corticotrophin upon the work performance of adrenalectomized-hypophysectomized rats", Acta Endocrinol, vol. 14, no. 2 (published Oct 1953), pp. 93–8, doi:10.1530/acta.0.0140093, PMID 13113828
Sources: en.wikipedia.org
==== Artificial Pancreas (AP) Systems ==== In 2006, Breakthrough T1D launched the Artificial Pancreas Consortium, allocating $6 million in grants to investigate the benefits of technology controlling blood-glucose levels to accelerate the availability of the artificial pancreas (AP). AP systems integrate three components—a CGM, an insulin pump, and an algorithm—to measure blood sugar, then calculate and administer, or withhold, insulin with minimal user input. In 2016, the FDA approved the first hybrid closed-loop, or AP, system.
== See also == 30mm DS30M Mark 2 Automated Small Calibre Gun British automated mount with 30 mm Bushmaster II Bushmaster III 35/50 mm chain gun Bushmaster IV 40 mm chain gun List of crew-served weapons of the U.S. Armed Forces List of weapons of the United States Marine Corps M230 30 mm automatic cannon Mark 38 25 mm Machine Gun System Bushmaster II 30 mm chain gun Oerlikon KBA 25 mm automatic cannon Shipunov 2A42 30mm automatic cannon
Colombia has more than 3,950 research groups in science and technology. iNNpulsa, a government body that promotes entrepreneurship and innovation in the country, provides grants to startups, in addition to other services it and institutions provide. Colombia was ranked 71st in the Global Innovation Index in 2025. Co-working spaces have arisen to serve as communities for startups large and small. Organizations such as the Corporation for Biological Research (CIB) for the support of young people interested in scientific work has been successfully developed in Colombia. The International Center for Tropical Agriculture based in Colombia investigates the increasing challenge of global warming and food security. Important inventions related to medicine have been made in Colombia, such as the first external artificial pacemaker with internal electrodes, invented by the electrical engineer Jorge Reynolds Pombo, an invention of great importance for those who suffer from heart failure. Also invented in Colombia were the microkeratome and keratomileusis technique, which form the fundamental basis of what now is known as LASIK (one of the most important techniques for the correction of refractive errors of vision) and the Hakim valve for the treatment of hydrocephalus. Colombia has begun to innovate in military technology for its army and other armies of the world; especially in the design and creation of personal ballistic protection products, military hardware, military robots, bombs, simulators and radar. Some leading Colombian scientists are Joseph M.
Sources: en.wikipedia.org
== Autobiographical nature == A Scanner Darkly is a fictionalized account of real events, based on Dick's experiences in the 1970s drug culture. Dick said in an interview, "Everything in A Scanner Darkly I actually saw." Between mid-1970 (when his fourth wife Nancy left him) and mid-1972, Dick lived semi-communally with a rotating group of mostly teenage drug users at his home in Marin County, described in a letter as being located at 707 Hacienda Way, Santa Venetia. Dick explained, "[M]y wife Nancy left me in 1970. I got mixed up with a lot of street people, just to have somebody to fill the house. She left me with a four-bedroom, two-bathroom house and nobody living in it but me. So I just filled it with street people and I got mixed up with a lot of people who were into drugs." During this period, the author ceased writing completely and became fully dependent upon amphetamines, which he had been using intermittently for many years. "I did take amphetamines for years in order to be able to—I was able to produce 68 final pages of copy a day," Dick said. The character of Donna was inspired by an older teenager who became associated with Dick sometime in 1970; though they never became lovers, the woman was his principal female companion until early 1972, when Dick left for Canada to deliver a speech to a Vancouver science fiction convention. This speech, "The Android and the Human", served as the basis for many of the recurring themes and motifs in the ensuing novel.
Pornanong Aramwit (Thai: พรอนงค์ อร่ามวิทย์, RTGS: Phon-anong Aramwit; born 1970) is a pharmaceutical scientist, pharmacist, academic, and author. She serves as the Vice President in Research and Innovation at Chulalongkorn University (CU) and is also a member of the university's Council, Administrative Board of the National Innovation Agency, and the Royal Society of Thailand. Aramwit's research has encompassed protein research, including silk proteins, biomaterials, tissue engineering, and herbal substances. She has conducted clinical studies in nephrology and dermatology, focusing on materials for wound healing applications. She is an inventor of medical devices and in the food industry, and has received awards including the Merits of Leadership Award Grand Officer Level: Number of the cross 1156 from the UK, the Merits of Innovation Grand Officer Level: Number of the cross 30705 from France, and the Merits of Innovation Ribbon of Honor: Number of the cross 16834 from Belgium, as well as from the European Union and Spain. Additionally, she was awarded the 2018 Ambassador Award for Innovator with Outstanding Achievements, the 2019 Outstanding Professional Women Award by the Federation of Business and Professional Women of Thailand, and the 2024 National Outstanding Researcher Award by the National Research Council of Thailand (NRCT). Aramwit has authored more than 220 peer-reviewed articles, authored/co-authored several books and book chapters, and has 20 patents.
The sessions were produced by Joe Foster, but McGee, unsatisfied with Foster's work, remixed the A-side, although the B-side, a cover version of Syd Barrett's "Vegetable Man", remained credited to Foster. The band were gaining increasing attention from the music press at this time with Neil Taylor of the NME describing them as "the best band in the world". Dalglish left in November 1984 after a dispute over money and was replaced shortly afterwards by Gillespie who had also formed Primal Scream two years earlier in 1982. "Upside Down" topped the UK Indie Chart in February 1985 and then again in March and stayed on the chart for 76 weeks, selling around 35,000 copies in total, making it one of the biggest-selling indie singles of the 1980s. Playing in front of small audiences, during early shows the Mary Chain performed very short gigs, typically fueled by amphetamines and lasting around 20 minutes, and played with their backs to the audience, refusing to speak to them. In late December 1984, the band performed as part of the ICA Rock Week. During their performance, bottles were thrown on stage, with press reports exaggerating events and claiming that there had been a riot, and national newspaper The Sun running a story on the band concentrating on violence and drugs, the band attracting the tag "The new Sex Pistols". That led several local councils to ban the band from performing in their area.
Reddy's path into new drug discovery involved targeting specialty generics products in western markets to create a foundation for drug discovery. Development of specialty generics was an important step for the company's growing interest in the development of new chemical entities. The elements involved in creating a specialty generic, such as innovation in the laboratory, developing the compound, and sending the sales team to the market, are also stages in the development of a new specialty drug. Starting with specialty generics allowed the company to gain experience with those steps before moving on to creating brand-new drugs. Reddy's invested heavily in establishing R&D labs and is the only Indian company to have significant R&D being undertaken overseas. Dr. Reddy's Research Foundation was established in 1992 and in order to do research in the area of new drug discovery. At first, the foundation's drug research strategy revolved around searching for analogues. Focus has since changed to innovative R&D, hiring new scientists, especially Indian students studying abroad on doctoral and post-doctoral courses. In 2000, the Foundation set up an American laboratory in Atlanta, dedicated to discovery and design of novel therapeutics. The laboratory is called Reddy US Therapeutics Inc (RUSTI) and its main aim is the discovery of next-generation drugs using genomics and proteomics. Reddy's research thrust focused on large niche areas in western markets – anti-cancer, anti-diabetes, cardiovascular and anti-infection drugs.
Sources: en.wikipedia.org
The most common approach is liquid chromatography with tandem mass spectrometry after extraction from blood or urine. Immunoassays exist but are generally treated as screening tools because of cross-reactivity.
Dry lyophilised powder is normally kept frozen and protected from moisture and light. Dissolved material is handled cold and used promptly to limit degradation.
It is not licensed as a medicine in major markets and is distributed as a research chemical. Sports organisations prohibit its use, and some countries restrict import and supply.
TB-500 is a name used for a short synthetic peptide fragment taken from the actin-binding region of thymosin beta-4. Material sold under this label is usually a lyophilized powder supplied for laboratory research rather than a licensed medicine. The commonly cited sequence is LKKTETQ.